North America leads the global cord blood banking services market, holding a 39.54% share in 2025. Growing awareness of stem cell preservation, expanding applications in hematological and genetic ...
Direct access to custom cell banks made from authenticated ATCC cell lines. Custom cell banking under cell culture quality standards approved by ATCC. Improved assay precision by the use of ...
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange ...
SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary ...
Consolidated revenues for the third quarter of fiscal 2025 were $7.83 million compared to $8.07 million for the third quarter of fiscal 2024, a 3% decrease. Net Income The Company reported net income ...
acCELLerate, a manufacturer of assay-ready frozen cells has established an agreement with ATCC a global biological resource and standards organization. Under the agreement, acCELLerate will produce ...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2025 Financial Results Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”, “Cryo-Cell”), the world’s first ...
acCELLerate produces custom cell banks, MCBs, WCBs and assay ready instaCELLs for drug discovery and bioassay in biologics potency testing. acCELLerate, a manufacturer of assay-ready frozen cells has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results